nice_logo

NICE recommend Migalastat for the treatment of Fabry

NICE recommend Migalastat for the treatment of Fabry disease for individuals over the age of 16 years with an amenable mutation. The National Institute for Health and Care Excellence (NICE) has today released their final decision (FED) to recommend Migalastat for the treatment of Fabry in people over 16 years of age with an amenable … Continue reading “NICE recommend Migalastat for the treatment of Fabry”

Read More

Subscribe to Our Newsletter